All rights reserved.
Product information
Executive Summary
Transforming healthcare for people living with chronic conditions.
Kitea Health is a digital health company improving care for hydrocephalus patients through an implantable pressure sensor that enables continuous, remote monitoring. Implanted during routine shunt surgery, the device helps reduce false alarms, which cause about 70% of hospitalisations, while enabling proactive, personalised care. With 1 million patients in the U.S., Kitea targets a $2B market and projects $165M in device and $25M in recurring revenue annually.
The company has completed adult trials, started pediatric studies, and received FDA Breakthrough Device designation. Backed by $20M+ in funding and led by a seasoned medtech team, Kitea is raising a $7–10M Series A to support regulatory approval and market expansion. Kitea have hit their first close for this round with a term sheet led by Icehouse Ventures.
A full DD room is available - for access, please contact Camille camille@mainlandangels.nz
Pitch video link here.
Problems
High rate of false alarms
- Around 70% of hospitalisations for hydrocephalus are unnecessary, causing stress for patients and inefficiencies for healthcare providers.
Limited access to continuous monitoring
- Intracranial pressure is typically measured only during hospital visits, making it difficult to track changes or respond proactively to complications.
Financial strain on healthcare systems
- Unnecessary admissions result in lost revenue for hospitals and increased costs across the system, highlighting the need for more efficient care delivery.
Solutions
Implantable pressure sensor
- The device is inserted during routine shunt surgery with no additional surgical cost, enabling continuous, real-time pressure monitoring without repeated hospital visits.
Remote monitoring and patient services
- Data is securely transmitted for ongoing monitoring, generating alerts, supporting patient education, and enhancing engagement while reducing unnecessary hospitalisations.
Analytics and hospital integration
- Kitea’s platform provides actionable insights through data analytics, informing clinicians when intervention is needed and improving the efficiency and cost-effectiveness of care delivery.
Market Opportunity
Large Market Potential
- Targets $2B hydrocephalus (1M U.S. patients) and $9B heart failure markets
- Remote pressure-monitoring positioned as future standard care
Unmet Clinical Need
- Solves 70% of false-alarm ER visits in hydrocephalus
- Backed by FDA Breakthrough Designation and key hospital partnerships
Strategic Exit Readiness
- Positioned for acquisition (e.g., Medtronic/J&J) post-FDA approval
- Leverages strong regulatory and industry advantages
Competitive Advantages
First-to-Market Wireless Monitoring
- Only FDA-designated wireless ICP monitor for home use
- Eliminates need for invasive hospital pressure measurements
- Works with any shunt type (unlike competitor solutions)
Clinical & Economic Value Proposition
- Reduces false alarms by 70%, saving hospitals $3B annually
- Enables proactive care through continuous data analytics
- Reimbursement pathways already established in U.S.
IP Protection & Scalability
- 4 patent families covering core wireless sensing technology
- Designed for high-volume manufacturing from inception
- Platform adaptable to multiple chronic conditions
Please see key documents for the Pitch Deck and Company Comparison.
To indicate your interest in this deal, please click the invest button above. You are able to change or withdraw your order prior to the capital raise ending.
This deal is arranged through Mainland Angel Investors (MAI), and this page is maintained by MAI. The offer has been made available to you as MAI believes you are a wholesale investor and member of MAI. Neither MAI nor Catalist makes any representation as to any lack of errors or omissions in the investment information provided. If you believe there is any inaccuracy in these records, please contact Camille at Camille@mainlandangels.nz in the first instance.
© Catalist Markets Limited 2025. All rights reserved.
